Lewy Body Dementia Treatment Market

Introduction

Key Insights- Lewy Body Dementia Treatment Market

• Global sales of lewy body dementia treatment were valued at over US$ 3,500 Mn in 2018, in line with wide-spread prevalence of lewy body dementia and subsequent need for effective treatment.
• Cholinesterase inhibitors, valued at over US$ 2,100 Mn in 2018, will continue to remain the most lucrative category, followed by antipsychotic drugs. The minimal side effects associated with these two drug types are among the key reasons fuelling demand for these products.
• North America will remain the largest market for lewy body dementia treatment in 2019 and beyond, owing to appropriate dementia drug regulations and superior healthcare infrastructure in the region.
• East Asia is anticipated to emerge as the fastest-growing market for lewy body dementia treatment, as China and India spearhead demand with an ever-growing geriatric population

Key Growth Drivers - Lewy Body Dementia Treatment Market 

• Government initiatives aimed at creating awareness about lewy body dementia treatment are likely to uphold growth of the market. For instance, the US has signed into a law the BOLD Infrastructure for Alzheimer’s Act, an initiative aimed at forming a public health model against Alzheimer’s disease and other dementias. The law would sanction approx. US$ 100 Mn over a period of five years to enhance public education, reinforce numerous dementia initiatives being taken by various health and social service agencies, and collect and distribute data related to cognitive decline. Additionally, the increase in funding for lewy body dementia treatment has been reinforced by the novel R&D initiative by the National Institutes of Health (NIH).
• Increasing prevalence of lewy body dementia and the absence of concerned drugs to manage this ailment is influencing pharma companies to invest in R&D. Currently, Alzheimer’s treatment drugs are used for managing lewy body dementia; however, it is highly likely that a range of generic drugs will proliferate the market in the near future.
• The high cost of lewy body dementia treatment has prompted healthcare providers to bring certain aspects under the ambit of reimbursements. Favorable regulations pertaining to lewy body dementia treatment have meant that economically weaker sections of the society have access to quality care, which in turn has opened up opportunities for pharmaceutical companies.
• The burgeoning number of performed clinical trials for lewy body dementia treatment is underpinning gains in the market by bolstering the efficiency of the existing treatment options. Ongoing treatment trials for better lewy body dementia medication have the potential to drive market growth substantially, provided these trials result in successful outcomes.

Key Challenges Faced by Stakeholders in Lewy Body Dementia Treatment Market 

• The adverse effects of drugs used in lewy body dementia treatment are denting consumer and caregiver confidence, creating significant challenges for market growth. For instance, long term exposure to widely used cholinesterase inhibitors for symptomatic treatment of lewy body dementia can cause side effects, such as vomiting, diarrhea, weight loss, and insomnia. The numerous side effects associated with lewy body dementia treatment drugs have been restricting the growth of lewy body dementia treatment market.
• Although reimbursement policies are available in certain countries, governments in various countries are yet to offer support for lewy body treatment. Considering the high cost of lewy body dementia treatment, a significant population does not receive continuous care, leading to limited drug sales. Furthermore, lewy body dementia treatment requires long-term care, with various complications triggering the cost of treatment over time. The numerous technical, regulatory and economic constraints imposed during the development process of a drug remain a significant cost driver.

Lewy Body Dementia Treatment Market – The Competitive Landscape 

• Swedish research-based biopharma company, BioArctic AB, announced that AbbVie has attained the FDA approval of IND application for ABBV-0805 for the treatment of individuals with Parkinson’s disease. The alpha-synuclein-targeting ABBV-0805 is the most advanced treatment in-licensed by AbbVie from BioArctic in December 2018. The antibody has been evaluated as a disease modifying treatment for Parkinson's disease.
• Sumitomo Dainippon Pharma Co., Ltd., a Japan-based pharmaceutical company, has signed a joint research agreement with Aikomi, Ltd. to build medical devices to relieve and prevent behavioral and psychological symptoms of dementia.
• Takeda Pharmaceutical Company Limited has announced the completion of acquisition of Shire plc. With this acquisition, Takeda Pharmaceutical has become a global, value-based, research and development driven biopharmaceutical leader headquartered in Japan.

Other players operating in the lewy body dementia treatment market and profiled in the report include BioArctic AB, Sumitomo Dainippon Pharma Co., Ltd., Jazz Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, Mylan NV, Sanofi AG, Teva Pharmaceuticals, GlaxoSmithKline, Eisai Co., Ltd., Takeda Pharmaceutical Company Ltd., Allergan Plc., Janssen Pharmaceuticals, Inc., Bausch Health Companies Inc., and Mallinckrodt Pharmacauticals.

Manufacturers Prioritizing Novel Product Launches to Boost Market Sustenance 

The rise in ageing population has been gradually increasing the patient pool for lewy body dementia treatment market, with leading manufacturers working on introducing new products tailored to solely focus on lewy body dementia.

Pharma companies are focusing on the development of highly innovative and competitive pipeline products. To capitalize on the changing healthcare patterns, manufacturers are diversifying their treatment offerings and business expansion via strategic tie-ups with primary care hospitals and clinics in the Asian and European countries.

Scope of the Report 

Lewy Body Dementia Treatment Market - Research Methodology

The Fact.MR study report on lewy body dementia treatment market offers an exhaustive analysis and assessment on worldwide lewy body dementia treatment market, which has been compiled with the aid of a proven and tested research methodology that includes primary and secondary phases.

This research methodology helped the analysts arrive at perceptive insights into the growth course of lewy body dementia treatment market during the foreseeable period. Data and insights compiled for lewy body dementia treatment market further undergo numerous stages of validation and examination before they got placed in the global lewy body dementia treatment market report. The authenticity of the market statistics compiled and evaluated for the lewy body dementia treatment market is inherited from the highly reliable research methodology of Fact.MR, which promises full reliability and high precision in terms of data and insights on lewy body dementia treatment market.

The Fact.MR report on lewy body dementia treatment market provides an exhaustive analysis of the lewy body dementia treatment market roadmap during the forecast period 2018-2028.

The report on lewy body dementia treatment market sheds light on diverse opportunities in the lewy body dementia treatment market space over the foreseeable period for the stakeholders to make a note of for decision-making. The report on lewy body dementia treatment market also offers a comprehensive segmental analysis, wherein all the lucrative segments are given in detail in tandem with their performance during the assessment period.

Lastly, the report on lewy body dementia treatment market features a competitive landscape that provides details about different companies operating in the global market space, along with their unique strategies to gain a competitive edge in the global market space.

Chapter 1- Lewy Body Dementia Treatment Market- Executive Summary

The report on lewy body dementia treatment market commences with a brief and concise executive summary that provides a crisp and quick view of the overall lewy body dementia treatment market in tandem with demand side trends, supply side trends, indication roadmap and recommendations to witness growth in global market space.

Chapter 2- Lewy Body Dementia Treatment Market- Market Overview

The second chapter of the report on lewy body dementia treatment market provides a market overview, along with a detailed market coverage and market definition, scope, and challenges being faced by the stakeholders.

Chapter 3- Lewy Body Dementia Treatment Market- Key Market Trends

The third chapter of the report on lewy body dementia treatment market provides a detailed information about the key trends influencing the market growth. This chapter also talks about the latest drug innovation in tandem with the key development trends in the lewy body dementia treatment market.

Chapter 4- Lewy Body Dementia Treatment Market- Key Success Factors

The fourth chapter of the report on lewy body dementia treatment market sheds light on the various key success factor that have been underpinning gains in the global lewy body dementia treatment market. This chapter covers pipeline assessment, disease treatment pathophysiology, key regulations, and disease epidemiology.

Chapter 5 - Global Lewy Body Dementia Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2013-2017 and Forecast, 2018-2028

In the fifth chapter of the report on lewy body dementia treatment market, information about the demand for lewy body dementia treatment has been provided in detail. This chapter talks about the significant numbers, such as historical market value, the current and future market value in (US$ Mn) projections, Y-o-Y growth trend analysis and absolute $ opportunity analysis.

Chapter 6 - Lewy Body Dementia Treatment Market- Key Success Factors

The sixth chapter of the report on lewy body dementia treatment market sheds light on the market background to aid the readers understand the market in a better way. This chapter covers macro-economic factors, including global GDP growth outlook and global healthcare expenditure outlook.

A comprehensive information about value chain, forecast factors and their relevance & impact, in tandem with market dynamics has been offered in the report.

Chapter 7 - Global Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028, by Drug Type

The seventh chapter of the report on lewy body dementia treatment market provides information about the different drug types existing in the lewy body dementia treatment market. It sheds light on the key findings, historical market side, alongside current and future market size (US$ Mn) analysis by drug type for the historical as well as forecast period.

By drug type, the lewy body dementia treatment market can be segmented into cholinesterase inhibitors, antipsychotic drugs, carbidopa-levodopa, antidepressants, benzodiazepine, and Modafinil.

Chapter 8 - Global Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028, by Indication

This chapter of the report on lewy body dementia treatment market provides market information based on indication. Based on indication, the lewy body dementia treatment market can be bifurcated into dementia with lewy bodies, and pakinson’s disease.

Chapter 9 - Global Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028, by Distribution Channel

This chapter of the report on lewy body dementia treatment market provides information about the different types of distribution channels existing in lewy body dementia treatment market. Based on distribution channels, the lewy body dementia treatment market can be bifurcated into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

Chapter 10 - Global Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028, by Region

This chapter of the report on lewy body dementia treatment market provides information related to the market growth in different parts of the world. Based on region, the lewy body dementia market can be bifurcated into North America, Middle East and Africa (MEA), East Asia, South Asia, Latin America, Europe, and Oceania. This chapter will help market enthusiast get an idea about the market presence in these regions.

Chapter 11 - North America Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about North America lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth.

Chapter 12 – Latin America Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about Latin America lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth.

Chapter 13 – Europe Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about Europe lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth.

Chapter 14 – South Asia Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about South Asia lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth. The diverse countries in this region, including India, Thailand, Indonesia, Malasyia, and Rest of South Asia, have been analyzed on the basis of drug type, indication, and distribution channel.

Chapter 15 – East Asia Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about East Asia lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth. The diverse countries in this region, including China, Japan, and South Korea, have been analyzed on the basis of drug type, indication, and distribution channel.

Chapter 16 – Oceania Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about Oceania lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth. The diverse countries in this region, including Australia and New Zealand have been analyzed on the basis of drug type, indication, and distribution channel.

Chapter 17 – Middle East and Africa Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about Middle East and Africa lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth. The diverse countries in this region, including GCC countries, Israel, Iran, Turkey, and the Rest of Middle East and Africa, have been analyzed on the basis of drug type, indication, and distribution channel.

Chapter 18 – Emerging Countries Lewy Body Dementia Treatment Market Analysis 2013-2017 and Forecast 2018-2028

This chapter of the report on lewy body dementia treatment market talks about emergin countries in lewy body dementia treatment market in tandem with the regional trends influencing the regional market growth. The diverse countries analyzed in this region, including China, India, and Brazil, have been analyzed on the basis of drug type, indication, and distribution channel.

Chapter 19 – Competition Analysis- Lewy Body Dementia Treatment Market

This chapter in the lewy body dementia treatment market offers a deep analysis of the various manufacturers operating in the lewy body dementia treatment market and their product profiles.